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Abstract
The E6 oncoprotein produced by high-risk mucosal HPV stimulates ubiquitinylation and proteasome-dependent
degradation of the tumour suppressor p53 via formation of a trimeric complex comprising E6, p53, and E6-AP. p53 is
also degraded by its main cellular regulator MDM2. The main binding site of p53 to MDM2 is situated in the natively
unfolded N-terminal region of p53. By contrast, the regions of p53 implicated in the degradation by viral E6 are not fully
identified to date. Here we generated a series of mutations (Y103G, Y107G, T155A, T155V, T155D, L264A, L265A) targeting
the central folded core domain of p53 within a region opposite to its DNA-binding site. We analysed by in vitro and in vivo
assays the impact of these mutations on p53 degradation mediated by viral E6 oncoprotein. Whereas all mutants remained
susceptible to MDM2-mediated degradation, several of them (Y103G, Y107G, T155D, L265A) became resistant to E6-
mediated degradation, confirming previous works that pointed to the core domain as an essential region for the
degradation of p53. In parallel, we systematically checked the impact of the mutations on the transactivation activity of p53
as well as on the conformation of p53, analysed by Nuclear Magnetic Resonance (NMR), circular dichroism (CD), and
antibody probing. These measurements suggested that the conformational integrity of the core domain is an essential
parameter for the degradation of p53 by E6, while it is not essential for the degradation of p53 by MDM2. Thus, the
intracellular stability of a protein may or may not rely on its biophysical stability depending on the degradation pathway
taken into consideration.
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Introduction
The p53 protein is a key regulator of cell proliferation. In non-
dividing cells, p53 is tightly maintained at a steady-state level,
which decreases when cells enter S-phase to undergo proliferation
[1,2]. Various factors of deregulated cell proliferation, such as
genotoxic stress or oncogene expression, induce both the
accumulation of p53 and the modulation of its activities [3]. This
results in activation of a variety of molecular pathways leading
either to cell-cycle arrest, senescence, or apoptosis. Due to its
central role in cell cycle regulation, p53 is systematically
deregulated in cancers and other pathologies involving abnormal
cell proliferation.
P53 is a multifunctional 393-residue protein (fig. 1A). The
central core domain (residues 98–292) constitutes a single folded
unit that bears the sequence-specific DNA-binding activity of p53.
The core domain is flanked by modulatory regions including an N-
terminal transactivation domain (residues 1–42), a proline-rich
domain (63–97), a helical tetramerisation domain (324–355) and a
C-terminal regulatory domain (363–393). These regions modulate
the transcriptional activity of the core domain in response to
various ligands (proteins, damaged DNA) or modifications such as
phosphorylation or acetylation [4]. The three-dimensional struc-
ture of the core domain bound to its double-stranded DNA target
has unravelled the structural basis of p53 transcriptional activity
[5].
Genotoxic stress-induced p53 accumulation mainly results from
post-translational stabilisation [6–8]. Therefore, both the physio-
logical and pathological mechanisms of p53 turnover have been
extensively studied. The cellular MDM2 protein, first known as a
transcriptional target of p53, was found to act as a E3 ubiquitin-
ligase, which transfers ubiquitin (Ub) onto p53, thereby targeting it
to proteasome-mediated degradation [9,10]. Perturbation of
MDM2 function leading to enhanced degradation of p53 is a
key event in numerous cancers [11–14]. Enhancement of p53
degradation has also been recognised as one of the strategies used
by oncoviruses that stimulate cell proliferation for the sake of their
own life cycle [15]. Adenoviral proteins E1b 55k and E4 34k have
been shown to form a stable complex with p53 leading to its
enhanced ubiquitination and subsequent proteasome-mediated
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types has also been demonstrated to catalyse the ubiquitin-
mediated degradation of p53 [18–20]. E6 is a small protein of
about 150 residues composed of two 70-residue zinc-binding
domains [21–23]. E6 interacts with E6AP, a 850-residue E3
ubiquitin-ligase [24–26]. E6AP contains an E6-binding site within
a central 18-residue stretch comprising the ‘‘LxxLL’’ motif that is
found in several other targets of E6 [27,28]. p53 has been
proposed to contain two distinct E6-binding sites [29–31]. The C-
terminal modulatory domain (residues 356–393) has been
suggested to contain a primary E6-binding site recognised by all
E6 proteins of both low- and high-risk HPV types, but this
interaction has no role in E6-induced p53 degradation [32,33].
The core domain of p53 appears to contain a secondary E6-
binding site restricted to E6s of high-risk HPVs. E6 binding to this
secondary site is E6AP-dependent and is required for p53
ubiquitination and subsequent degradation [34]. The precise
location of this site within the p53 core domain structure is still
unknown.
Li and Coffino [30] showed that aminoacids 100–150 of p53
contain a degradation domain and hypothesized this region as the
second binding site for high risk E6. Additionally, Gu et al. [29]
proposed that p53 has a unique sequence element within the core
domain (aminoacids 92–112) that acts as a signal for MDM2-
mediated degradation and the binding of oncoproteins, which
direct p53 degradation towards proteasome pathway. This
secondary site was also required for E6/E6AP-mediated p53
ubiquitination and subsequent degradation, whereas the primary
site was dispensable for these activities [29]. More recently a
secondary MDM2 binding site was suggested to exist in the flexible
loop which links S9–S10 b-strands of the p53 core domain and
proposed as a regulatory element modulating p53 ubiquitination
[35]. NMR and fluorescence anisotropy measurements have also
suggested that a second MDM2 binding site is located within p53
core domain [36]. On the other hand, Bech-Otschir et al. [37]
observed that phoshorylation of T155, a threonine residue also
situated in the core domain, by the COP9 signalosome (CSN)
appeared to be important for p53 degradation by the Ub-26S
proteasome system and that replacement of T155 by valine
stabilized p53 in HeLa cells.
Remarkably, when the above-mentioned mutations are plotted
on the structural model of p53, it can be observed that they are all
focused on the same region of the p53 core domain. A fragment of
the region defined by Gu et al. in 2001 [29], spanning
approximately residues 99–107, forms an extended N-terminal
tail structure that runs on the surface of the core domain. This N-
Figure 1. Localization of residues within the structure of p53 core domain. (A) Schematic view of the domain structure of p53. The 393-
residue p53 protein comprises an N-terminal transactivation domain (blue), followed by a proline-rich region (purple), a central DNA-binding core
domain (green), a tetramerization domain (red) and a regulatory domain (yellow) at the extreme C-terminus. The regions of possible interaction
between p53 and MDM2 or p53 and HPV E6 are indicated. (B) Enlarged view of the three-dimensional structure of p53 core domain. Mutants analysed
for this study are all localised in the same tridimensional region, distal from the DNA binding site. The leucine 265 is shown in light green, the leucine
264 in dark green, the threonine 155 in orange, the tyrosine 103 in pink, the tyrosine 107 in purple and the region in yellow corresponds to the
residues 99 to 107. The b-strands are shown in blue (S7, S9 and S10) and the a-helix in red. The view was created from PDB entry: 1TSR using the
PyMOL software.
doi:10.1371/journal.pone.0025981.g001
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aromatic residues Y103 and Y107, which interact with residues
L264 and L265 that belong to the loop connecting b-strands S9
and S10 (fig. 1B). Moreover, the amino acid T155 highlighted by
Bech-Otschir et al. in 2001 [37] is also located in the vicinity of
these residues.
In the present work, we generated p53 constructs bearing
various mutations on key residues situated within the above
mentioned region of p53 core domain. E6 and MDM2 dependent
degradation and transactivation activity of the mutated p53
proteins were analysed both in vitro within cell extracts and in vivo
within a p53-null cell line. In addition, the incidence of the
mutations on the structural integrity of p53 was studied by circular
dichroism (CD) and NMR
1H-
15N correlation spectroscopies.
While mutants T155A, T155V and L264A were still degraded by
E6, the mutants Y103G, Y107G, T155D and L265A became
resistant to E6 mediated degradation. By contrast, all mutants
were still degraded by MDM2. Among the E6-resistant mutants,
Y107G, T155D and L265A appeared to have completely lost the
native p53 fold, whereas Y103G displayed a folded yet
significantly altered conformation.
Results
Mutation L265A protects p53 from E6-mediated
degradation
According to observations made by Shimizu et al. [35], the
aminoacids S261, L264 and F270 of p53 seem to be implicated in
the MDM2-dependent ubiquitination. On the other hand,
residues L264 and L265 are spatially close to the sequence
segment 92–112 that has been previously described as an
important region for the E6 mediated degradation via the 26S
proteasome [29]. This prompted us to generate two single-point
mutants of p53: p53-L264A and p53-L265A. HPV16 E6 as well as
the wild-type (WT) and mutant p53 proteins were synthesised as
35S-labeled proteins in a rabbit reticulocyte lysate translation
system. Lysates containing the appropriate labeled proteins were
then combined to analyse the E6-mediated degradation of the p53
mutants in vitro. p53-WT along with p53-L264A were efficiently
degraded in the presence of HPV16 E6, whereas p53-L265A was
found to be resistant to degradation in the same conditions (Fig. 2A
and B). Mutant L265A was also found to be resistant to HPV16 E6
degradation in vivo, in H1299 p53-null cells co-transfected with
vectors coding for the p53 mutant and HPV16 E6 protein
(Fig. 2C). Remarkably, in this assay the E6 cellular levels were
strongly increased in the presence of the proteasome inhibitor
ALLN (Calpain inhibitor I) (Fig. 2C, compare intensity of E6 band
between lanes 3 and 4 or between lanes 7 and 8), and this effect
was also observed in the absence of p53 (Fig. 2C, compare
intensity of E6 band between lanes 9 and 10). This result is
consistent with previous observations [38] demonstrating that E6
is ubiquitinated and degraded by the proteasome.
Mutations Y103A and Y107G protect p53 from E6
degradation
The sequence segment 92–112 that has been previously
described as an important region for the E6 mediated degradation
via the 26S proteasome [29]. Furthermore, residues Y103 and
Y107 of this segment are spatially close to residue L265 which we
have just identified as a key residue for E6 mediated p53
degradation (Fig. 1B). We first generated the multiple mutant p53-
99-107 in which the sequence
99SQKTYQGSY
107 was replaced
by the sequence
99GAGAGAGAG
107. Similar to p53-L265A, this
mutant was resistant to HPV16 E6-mediated degradation both in
vitro and in vivo (Fig. 3A and 3B). We then generated single point
mutants in which Y103 and Y107 were substituted by glycine.
Both p53-Y103G and p53-Y107G were resistant to HPV16 E6-
mediated degradation in vivo (Fig. 3C).
Mutation T155D but not T155A or T155V, protects p53
from degradation by HPV16 E6
The phoshorylation of T155 can modulate p53 stability via the
COP9 signalosome (CSN), which participates in p53 ubiquitina-
tion. The phoshorylation state of T155 was also described as
important in high-risk E6 induced degradation of p53 [37]. We
generated mutants p53-T155V, p53-T155A and p53-T155D. The
replacement of T155 by alanine or valine aimed to inactivate the
putative phosphorylation site, whereas its replacement by
aspartate aimed to mimic a constitutively phosphorylated
threonine. The mutant proteins p53-T155A and p53-T155V
were degraded in presence of HPV16 E6 in transfected H1299
cells, whereas p53-T155D was resistant to degradation mediated
by E6 (Fig. 3D).
All p53 core mutants are still degraded by MDM2
We also examined whether the various mutations altered the
MDM2-dependent degradation of p53 in H1299 cells. The major
binding site of MDM2 on p53 is located in the N-terminal
transactivation domain (residues 14–27) [39,40]. A secondary
putative MDM2-binding site has been reported in the p53 core
domain which seems to play a regulatory role in modulating p53
ubiquitination [35,36,41]. A vector expressing MDM2 was
cotransfected with vectors expressing the different mutants of core
domain of p53 full length in H1299 cells. All mutated proteins
were degraded in the presence of MDM2 demonstrating that none
of these mutations prevented MDM2 to bind and to degrade p53.
However, L265A, Y103G, Y107G, and the double mutant
Y103G/Y107G appeared slightly less sensitive to MDM2-
mediated degradation as compared to p53-WT (Fig. 4). As a
control, we used a vector encoding mutant p53-mutMDM2,
bearing the multiple mutations F19A/W23A/L26A altering the
primary binding site of p53 to MDM2. In contrast to all the core
domain mutants, p53-mutMDM2 was fully resistant to MDM2-
mediated degradation (Fig. 4).
Mutations Y107G, T155D and L265A, but not T155A,
T155V and Y103G, fully disrupt the capacity of p53 to
transactivate the p21 promoter
Next, we tested the ability of the p53 mutants to transactivate
the p21 gene promoter. First, the transactivation capacities of WT
and mutated p53 proteins were examined in the presence of the
p21 gene promoter using a luciferase reporter construct. The p53-
T155A, p53-T155V, and p53-Y103G mutants remained able to
transactivate the p21 luciferase reporter construct while p53-
Y107G, p53-T155D and p53-L265A failed (Fig. 5A). To confirm
these results, p53 mutant proteins were expressed ectopically in
H1299 cells and crude extracts were submitted to SDS-PAGE and
Western blot analysis. In H1299 cells, the expression of
endogenous p21 protein was induced in the presence of p53-
WT, p53-Y103G, p53-T155A or p53-T155V, but not in presence
of p53-Y107G, p53-T155D or p53-L265A (Fig. 5B).
L265 belongs to the loop connecting strands S9 and S10, which
is distal from the DNA-binding surface [42]. T155 and Y107 are
also distal from the DNA binding domain of p53. Therefore we
can exclude that the mutagenesis of these residues altered the
transactivation property by directly modifying the DNA-binding
site. More likely, the mutations T155D, L265A, and Y107G may
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proteins produced in rabbit reticulocyte lysates were incubated together at 28uC. Aliquots were removed at the indicated times before separation by
12% SDS-PAGE and exposition to photographic film. (B) Same experiment as in A, but levels of radiolabeled p53, after exposition to photographic
film, were quantified by densitometry (BIO-RAD, Quantity One Software). Mean values (AU) 6 standard deviation for three independent experiments
are shown. (C) H1299 cells were co-transfected by vectors for transient expression of HPV16 E6 and p53 proteins. Where indicated, 4 h prior to
harvesting, the medium was supplemented with the 26S proteasome inhibitor ALLN at a final concentration of 100 mM. 24 h after transfection,
extracted proteins were separated by 12% SDS-PAGE and analysed by Western-blotting using monoclonal anti-p53 antibody, polyclonal anti-actin
antibody and monoclonal anti-16-E6 antibody.
doi:10.1371/journal.pone.0025981.g002
Figure 3. Behaviour of p53 mutants in presence of E6. (A) Radiolabeled p53 (wild type and indicated mutants) and HPV16 E6 proteins
produced in rabbit reticulocyte lysates were incubated together at 28uC. Aliquots were removed at the indicated times before separation by 12%
SDS-PAGE and exposition to photographic film. (B, C and D) H1299 cells were co-transfected by vectors for transient expression of HPV16 E6 and p53
proteins. Where indicated, 4 h prior to harvesting, the medium was supplemented with the 26S proteasome inhibitor ALLN at a final concentration of
100 mM. 24 h after transfection, extracted proteins were separated by 12% SDS-PAGE and analysed by Western-blotting using monoclonal anti-p53
antibody, polyclonal anti-actin antibody and monoclonal anti-16-E6 antibody.
doi:10.1371/journal.pone.0025981.g003
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which indirectly disrupted the DNA binding activity of p53,
subsequently inactivating the capacity of p53 to induce p21 gene
transactivation.
p53-Y107G, p53-T155D and p53-L265A exhibited a
structural mutant conformational state
To investigate whether the Y107G, T155D and L265A
mutations altered the fold of p53, we used anti-p53 antibodies
known to distinguish between ‘‘native’’ (i.e., wild-type) and
‘‘mutant’’ (i.e., conformationally altered) conformations of p53
core domain [43].
The Pab 1620 antibody recognises preferentially wild-type p53
with native fold whereas the Pab 240 antibody recognises a buried
epitope on b-strand S7, which becomes accessible only upon
unfolding of this region [43,44]. Both p53-WT and p53 mutants
were transiently expressed in H1299 cells and the crude extracts
immunoprecipitated using either Pab 1620 or Pab 240 antibody
and detected by Western blot analysis (Fig. 6). p53-WT was
recognised exclusively by Pab 1620 antibody, indicating that it was
in its native conformation state. Similarly, the p53-Y103G and the
p53-T155A point mutants bound predominantly to Pab 1620
antibody which selectively recognises native p53. p53-T155V is
recognised by both antibodies which suggests a mixture of native
and non-native conformation. p53-Y103G is of particular interest
as this mutant has lost the capacity to be degraded by E6, yet
seems to retain a native-like conformation since it is preferentially
recognised by Pab 1620 antibody. By contrast, p53-L265A, p53-
Y107G and p53-T155D were predominantly recognised by Pab
240 suggesting that they have lost the native p53 conformation.
The mutant p53-Y103G core domain displayed a native
conformation
In order to confirm the observations obtained with conforma-
tion-sensitive antibodies, core domains of the human p53-WT
protein (p53core-WT), and the mutants p53-L265A (p53core-
L265A) and p53-Y103G (p53core-Y103G) were overexpressed in
E. Coli, purified and analysed by biophysical methods. Then, the
biophysical status of p53core-L265A and p53core-Y103G mutants
was examined and compared to p53core-WT.
We first recorded far-UV CD spectra of the three purified
samples (Fig. 7A). Usually, far-UV CD spectra are recorded in
order to estimate secondary structure contents. An accurate
estimate of contents requires recording data at wavelength as low
as possible and at least below 192 nm. However, we were not able
to reach such a low wavelength with the p53core-L265A sample
due to the relatively high salt concentration that was required for
the stability of the sample. Nevertheless, comparison of CD spectra
of mutated p53 core domain samples with WT is sufficient to know
whether the secondary structure content is perturbed or not.
P53core-WT and p53core-Y103G spectra could be well superim-
posed, suggesting a similar secondary structure content (Fig. 7A).
By contrast, the p53core-L265A spectrum dramatically changed
compared to WT, suggesting that mutation strongly altered the
conformation of the core domain.
Thermal denaturation was also assessed in order to check and
compare thermal stability of the domains (Fig. 7B). Thermal
denaturation midpoints were 40 and 36uC for p53core-WT and
Figure 4. MDM2-mediated degradation of p53 mutants. H1299 cells were co-transfected by vectors for transient expression of MDM2 and p53
proteins. 24 h after transfection, extracted proteins were separated by 10% SDS-PAGE and analysed by Western blotting using monoclonal anti-p53
antibody, polyclonal anti-actin antibody.
doi:10.1371/journal.pone.0025981.g004
Figure 5. Transactivation activity of p53 mutants. (A) H1299 cells
were co-transfected by vectors coding for p53 proteins and a vector
expressing the reporter gene luciferase under the control of the p21
promoter (NT: Not Transfected). Crude cellular extracts were then
analysed by luminescence dosage (AU: Arbitrary Units). (B) H1299 cells
were co-transfected by vectors for transient expression p53-WT and
mutant proteins. 24 h after transfection, crude extracts were separated
on 12% SDS-PAGE and analysed by Western blotting using monoclonal
anti-p53 antibody, anti-p21 antibody.
doi:10.1371/journal.pone.0025981.g005
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p53core-Y103G mutant was thermodynamically destabilised as
compared to wild-type p53. However the thermal transition for
the p53-Y103G core domain mutant remained sharp suggesting
that this mutant remains cooperatively folded.
By contrast, the denaturation curve of the p53core-L265A
mutant displayed a very broad non cooperative transition centred
around 25uC. This observation suggests that p53core-L265A is
unfolded, displaying mainly random conformations.
To further analyse the effect of the mutations on p53
conformation, and validate the observations obtained with
antibodies, we produced
15N-labeled samples of p53 core domain.
The NMR
1H-
15N correlation spectrum of the p53core-WT core
domain recorded by NMR spectrometry matched formerly
published spectra (for reference and peak assignment see Wong
et al. [45]) (Fig. 7C). The p53core-WT spectrum displayed a well
dispersed peak pattern with a homogeneous linewidth character-
istic of a folded protein. By contrast, the spectrum of the p53core-
L265A had lost the characteristic peak distribution of wild-type
domain, and instead displayed signals in the region typical for
random coil conformation, together with a decrease in signal
intensities as well as linewidth broadening. These observations
indicated that the domain was in a non-native conformation (for a
reference showing a HSQC spectrum of unfolded p53core-WT see
Ru ¨diger et al. [46]). However the purified p53-L265A core domain
was soluble and monodisperse after gel filtration and could be
concentrated to relatively high concentration for NMR investiga-
tion. p53core-T155V and p53core-Y107G point mutants also
displayed spectral characteristics of non-folded proteins, although
their purification and concentration resulted more difficult than
for p53-L265A core domain (data not shown).
The
1H-
15N correlation spectrum of p53-Y103G mutant core
domain displayed a dispersed peak pattern characteristic of a
folded protein, and retained at least 80% of the cross peaks
observed for the p53-WT core domain. However, the linewidth of
the cross peaks was more heterogeneous than for the wild-type
protein, suggesting that some regions in the mutant may be prone
to conformational exchange and/or self-association. In addition,
close to 20% of the original cross-peaks of the WT core domain
were not found, whereas some very intense additional peaks
appeared in a region characteristic for residues in random
conformations (8 to 8.5 ppm). Interestingly, most of the cross
peaks of the p53-WT spectrum which were no more observed in
the mutant p53core-Y103G spectrum corresponded to residues of
the b-strand S10 directly in contact with the loop 92–112
described by Gu et al. [29] and containing the Y103 and Y107
residues. These observations suggest that the p53-Y103G mutant
core domain is folded yet presents significant conformational
alterations as compared to the wild type core domain. Most
probably, these conformational alterations mainly concern resi-
dues spatially close to residue 103, i.e. residues situated in the N-
terminal segment and in b-strand S10.
Discussion
In the present work we studied the importance of residues
within a region of p53 core domain that has been reported to
contain a binding site for E6 from high-risk HPVs [29,30,37], and
MDM2 [35,36,41]. Consistent with previous reports where
chimeras of p53 with the 92–112 region from p73 were resistant
to HPV16 E6-mediated degradation [29], we observed that
multiple point mutagenesis of the strech 99–107 was sufficient to
prevent p53 degradation in the presence of HPV16 E6 both in vitro
and in vivo. In the structure of p53 core domain Y103 and Y107
are in contact with L264 and L265 situated in the linker between
S9 and S10 segments. The single point mutation of Y107 to
glycine protected p53 from HPV16 E6-mediated degradation,
probably due to the alteration of the fold of the core domain.
Indeed, mutant Y107G failed to transactivate the p21 promoter
and it did not bind to the Pab 1620 antibody that selectively
recognises the folded conformation of p53, whereas it bound to the
Pab 240 antibody directed against a buried epitope on b-strand S7
(residues 212–217), which becomes accessible upon unfolding of
this region. On the other hand, replacement of Y103 by glycine
was found to protect from the E6-mediated degradation, and
although it impacted on the conformation of the resulting protein,
it did not disrupt its ability to fold.
The replacement of amino acid L264, reported to be implicated
in the ubiquitination of p53 by MDM2 [35], to alanine had no
effect on p53 degradation in the presence of HPV16 E6 or MDM2
(data not shown). However, replacement of L265 to alanine
protected p53 from HPV16 E6-mediated degradation in vitro.
Interestingly, when transiently expressed in H1299 p53-null cells,
p53-L265A mutant retained its susceptibility to MDM2-mediated
degradation but resisted to HPV16 E6-mediated degradation and
displayed an impaired transcriptional activation capacity. Further
investigation using Pab 240 and Pab 1620 [43] showed that p53-
L265A had a ‘‘mutant’’ conformation. Both CD and NMR results
showed that the p53core-L265A had a mainly unfolded confor-
mation. Taken together these results show that a p53 mutant
possessing an unfolded core domain remains capable of interacting
with and be degraded by MDM2. However, we noticed that p53-
L265A, together with p53-Y103G and p53-Y107G, were less
Figure 6. Conformation of p53 mutants. H1299 cells were transfected by vectors for transient expression of p53 proteins. Cell lysates were
incubated with mouse monoclonal anti-p53 antibody, either the Pab 1620 recognising only the ‘‘wild-type’’ conformation epitope or the Pab 240
recognising only the ‘‘mutant’’ conformation epitope. Immune complexes and whole lysates (input) were separated by 12% SDS-PAGE and subjected
to Western blotting using antibodies against p53 (polyclonal rabbit).
doi:10.1371/journal.pone.0025981.g006
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This may be explained by a decreased binding of MDM2 to its
putative target site within the core domain [47], which may
influence the ubiquitination level of p53 [35]. Alternatively, the
unfolding or conformational alteration of the core domain due to
these mutations might provoke some aggregation of the mutants in
vivo, thereby decreasing the efficiency of their recognition and
degradation by MDM2.
p53 is subjected to an array of post-translational modifications
that regulate its stability and consequently half-life that in turn
influences the expression of p53 target genes. In particular
phosphorylation generally results in its stabilization [4,48,49]. It
has been reported that the phosphorylation status on T155 is
important for the E6-mediated degradation of p53 in HeLa cells
[37]. We observed that the replacement of T155 by aspartate
protected p53 from HPV16 E6-mediated degradation but not
when T155 was substituted by alanine or valine, and that all
mutant proteins were still degraded by MDM2. When transfected
in H1299 cells, p53-T155A and p53-T155V transactivated the
p21 promoter but not p53-T155D. These data suggested a
possible effect of the p53-T155D mutation on p53 fold. Indeed,
while p53-T155A and, to some extent p53-T155V, were
Figure 7. Biophysical analysis of Wt and mutant p53 core domain. (A) Comparison of different p53 core domain proteins (WT, L265A, Y103G)
with respect to secondary structure content by CD. The spectra were recorded in 20 mM sodium phosphate (pH 6.8), 20 mM NaCl, 2 mM DTT at
10uC. The far-UV spectrum of the p53wt and p53Y103G are similar and show characteristics of folded proteins with a minimum at 201 nm while the
spectrum of the L265A p53 core domain suggests a large proportion of unfolded protein as indicated by the shift of the minimum towards smaller
wavelength and a negative signal at 200 nm. (B) Thermal denaturation of the p53 core domain proteins monitored by far-UV CD spectroscopy at
210 nm. The spectra were recorded in 20 mM sodium phosphate (pH 6.8), 50 mM NaCl, 2 mM DTT. For clarity, spectra have been offset by 10 mdeg
between each curve. (C)
1H-
15N correlation spectra of p53 core domain (residues 94–312) acquired at 10uC on a Bruker DRX600 spectrometer
equipped with a z-gradient triple resonance cryoprobe. The p53WT core domain is represented in black (left panel), the p53L265A core domain in red
(middle panel) and the p53Y103G core domain in blue (right panel).
doi:10.1371/journal.pone.0025981.g007
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T155D mutant was recognised by Pab 240 specific of ‘‘mutant’’
conformation. However, our observations regarding p53-T155V
differ to previous work that indicated this mutant was stabilized in
HeLa cells [37]. In our experiments p53-T155V was partially
recognised by both antibodies Pab 1620 and 240. Moreover,
according to 1D NMR spectra, this mutant adopted a folded
conformation (data not shown). In addition, p53-T155V and
HPV16 E6 coding vectors were co-transfected in H1299 p53-null
cells, while in the previous study only p53-T155V mutant protein
was ectopically expressed in HeLa cells. The increase in stability of
p53-T155V observed by Bech-Otschir et al. may be due to a
fraction of p53 produced with an altered conformation that was
resistant to HPV18 E6 or to a titration of endogenous HPV18 E6.
Interestingly, the three unfolded mutants p53-Y107G, p53-
T155D, and p53-L265A were still degraded by MDM2. Several
studies positioned a second binding site for MDM2 in the core
domain of p53 [35,36,41,50,51] but none of them used a
mutagenesis approach. Our results suggested that changes induced
by mutants p53-L265A, p53-Y107G, and p53-T155D in the
folding of the core domain did not disturb the putative secondary
docking site of MDM2 on p53 core domain nor inhibit MDM2-
dependent ubiquitination of p53. In light of our observations we
can hypothesize that the second binding site of MDM2 might be a
flexible segment of the core domain, which does not require a fully
folded context for binding to its partners.
While all core domains mutants of p53 remained susceptible to
MDM2-mediated degradation regardless of their conformational
status, we found that all the mutants which became protected
against degradation by the viral E6 oncoprotein presented an
unfolded or conformationaly altered core domain. On the one
hand, this indicates that the conformation of the core domain is an
essential parameter for the degradation of p53 by E6. On the other
hand, it is possible that some of the residues which we have
mutated participate in the binding interface between E6 and p53.
However, at present we cannot draw any definite conclusion on
this point. It is important to notice that, would we have skipped all
the experiments aimed at analysing p53 folding and conforma-
tional status, we would have probably concluded that all the
residues whose mutation inactivated the susceptibility of p53 to E6
degradation, were directly involved in the E6-p53 interface. This
emphasizes the strategic importance of ‘‘fold-checking’’ biophys-
ical experiments for the correct analysis of mutagenesis data, and
also points to the limitations inherent to site-directed mutagenesis
approach. To get definite answers on the E6-p53 interaction
interface, we may have to wait for high-resolution structural
studies of the E6-E6AP-p53 complex.
Materials and Methods
Plasmids
Using standard PCR protocols and the plasmid vector pCMV-
neo-bam coding for p53 as the DNA template (pC53-SN3) [52],
DNA sequences encoding the various forms of human p53 were
obtained. These sequences were inserted in the expression vector
plasmid pCDNA3-Amp. Several mutants were produced and
named p53-T155A, p53-T155D, p53-T155V, p53-L264A, p53-
L265A, p53-Y103G, p53-Y107G, p53-Y103G/Y107G, and p53-
99-107 (where the region
99SQKTYQGSY
107 was replaced by
99GAGAGAGAG
107). HPV16 E6 sequence was inserted into
pXJ40 allowing expression of E6 (158 amino acids) controlled by
SV40 promoter. The expression vector pCDNA-E6K2 encoding
the HPV16 E6 protein has previously been described by Giovane
et al. [53]. For the transfection of MDM2, we used the expression
vector pCOC-MDM2 described previously by Haupt et al. [54]
and kindly provided by Professor Moshe Ohren (Weismann
Institute, Rehovot, Israel).
GST fusion protein expression vectors were constructed using
the pETM30 expression vectors kindly provided by Gunter Stier
(EMBL, Heidelberg, Germany). DNA oligomers encoding the p53
wild-type and mutant core domain were inserted in to the
pETM30, a modified pET24d vector containing a N-terminal
His6-GST tag and a TEV protease cleavage site. This gave rise to
the vectors pETM30-WTcore, pETM30-L265Acore, and
pETM30-Y103Gcore.
Cells and transfection
H1299 cells (p53-null human non-small-cell lung adenocarci-
noma cells) were kindly provided by Professor Ingrid Hoffmann
(DKFZ, Heidelberg, Germany) and were maintained in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented with 10%
foetal bovine serum, Hepes and antibiotics. Various combinations
of plasmids were transfected into the H1299 cells by use of
lipofectamine (Invitrogen) according to the manufacturer’s in-
structions. For the co-transfection assays, we used 1 mg of each
plasmid, except for MDM2 where 5 times more was used.
Western blot analysis
The level of p53, HPV16 E6, actin or MDM2 was determined
by Western blotting. The cells were extracted in 150 mM NaCl,
50 mM tris HCl (pH 8), 5 mM EDTA, 1% NP40, 2 mM DTT
and an antiprotease cocktail (Complete EDTA-free, Roche). After
a short sonication step, the extract was clarified by centrifugation
at 160006 ga t4 uC for 20 min. Extracted proteins were then
separated by 12% SDS-PAGE and analysed by Western blot. The
membrane was incubated with different antibodies: mouse
monoclonal anti-p53 antibody (DO-1, Calbiochem), rabbit
polyclonal anti-p53 antibody (FL-393, Santa Cruz Biotechnology),
rabbit polyclonal anti-p21 antibody (C-19, Santa Cruz Biotech-
nology), rabbit polyclonal anti-actin antibody (A2066, Sigma-
Aldrich), mouse monoclonal anti-HPV16-E6 antibody (6F4,
Euromedex) and analysed by enhanced chemiluminescence
(Amersham Biosciences). For proteasome inhibitor assays, the
cells were treated for 11 h with 100 mM of calpain inhibitor ALLN
in 0.1% DMSO (Sigma-Aldrich). The cells were analysed 24 h
after transfection.
Immunoprecipitation analysis
Immunoprecipitation of p53 with antibodies Pab 1620 and Pab
240 (Calbiochem) was performed on H1299 total cell extracts.
25 mL of protein A sepharose resin was mixed on a wheel with one
antibody for two hours at 4uC in buffer B (0.2% v/v NP40,
150 mM NaCl, 10 mM tris, pH 7.5 and 2 mM EDTA), and then
the lysates containing the p53 mutant were added over night.
Subsequently, beads were washed three times with buffer B, three
times with buffer C (0.2% v/v NP40, 500 mM NaCl, 10 mM tris,
pH 7.5, and 2 mM EDTA) and once with 10 mM tris, pH 7.5.
In vitro degradation assay
35S-Labeled proteins were obtained by in vitro-translation using
the TnT Quick Coupled Transcription/Translation rabbit
reticulocyte lysate system (Promega) following the manufactures
instructions and using Promix
35S-labeled Cysteine and Methio-
nine (Promega). The lysates containing translated E6 protein
(25 mL) and the indicated translated p53 protein (10 mL) were
incubated at 28uC in the presence of 3 mM DTT, 100 mM NaCl,
25 mM Tris-HCl, pH 7.5 in a final volume of 50 mL. At the
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SDS sample buffer. Samples were separated by 12% SDS-PAGE
and the gel was incubated for 45 min in fix buffer (20% v/v
ethanol, 10% v/v acetic acid) and dried before exposure to a
BioMax MR film (Kodak). Levels of radiolabeled p53 were
quantified by densitometry (BIO-RAD, Quantity One Software).
Luciferase reporter gene assays
H1299 cells were transfected with a p21-luciferase plasmid and
with pCDNA-p53-WT or mutants. Twenty-four hours after
transfection, the cells were washed with PBS and scrapped in
1 mL of ice-cold PBS. After centrifugation, the cell pellet was
resuspended in 100 mL of buffer (100 mM KH2PO4, pH 7.8,
1 mM DTT) and incubated 20 min on ice and subsequently
cleared by centrifugation at 160006 g. A Bradford assay was
performed to determine the protein concentration of the cell
lysates. 50 mL of the cell lysate were incubated with 50 mLo f
luciferase reaction buffer (100 mM KH2PO4, 6 mM ATP,
0.75 mM CoenzymeA, 15 mM Mg2S04, 1 mM luciferine). The
luciferase activity was then measured by a luminometer.
Expression and purification of GST-p53 core domains
The core domain (residues 94–312 [45]) of the human p53 WT
protein (p53core-WT) and the mutants p53-L265A (p53core-
L265A) and p53-Y103G (p53core-Y103G) were cloned into
pET30 and expressed in E. coli strain BL21 (DE3). Overexpression
cultures were grown in unlabeled medium (CD) or in M9 minimal
medium with
15N labeled NH4(SO4)2 as a sole nitrogen source
(used for NMR
1H-
15N correlation spectroscopy) at 37uC until
OD600 reached 0.8. The cultures were then transferred to 20uC
and induced with 0.5 mM isopropyl a-D-thiogalactoside (IPTG)
over night. After induction of protein expression, bacteria were
collected by centrifugation and resuspended in buffer (50 mM
TrisHCl, 200 mM NaCl, 2 mM DTT, pH 6.8 supplemented with
2.5 mg/mL RNaseA, 2.5 mg/mL DNaseI and antiprotease
Cocktail-Complete EDTA-free, Roche). The suspension was
sonicated and centrifuged at 300006g for 60 min. Supernatants
were purified on a GST-Trap column (GE Healthcare) and the
purified GST-p53 core was cleaved with recombinant TEV
protease. p53 core domains were purified on a HiTrap-heparin
column (GE healthcare) and by size exclusion on superdex 75 pg
column (GE healthcare).
NMR Spectroscopy
Samples of p53-WTc (100 mM), p53-L265Ac (70 mM) and p53-
Y103Gc (125 mM) for NMR experiments were prepared in
20 mM phosphate buffer (pH 6.8), 200 mM NaCl, 2 mM DTT
and 10% D2O. Approximately 250 ml of samples were transferred
to 8 mm Shigemi tubes for data acquisition. In order to investigate
the folding state of the p53 core domain, NMR experiments were
conducted at 10uC on a Bruker DRX600 spectrometer equipped
with a z-gradient triple resonance cryoprobe.
1H-
15N SOFAST-
HMQC [55] data were acquired with 1024 complex points and a
spectral width of 4000 Hz in F2 (
1H) and 128 complex points with
2400 Hz in F1 (
15N). The recycle delay was 0.25 s and the number
of transients used was 1024. Data were processed using
XWINNMR (Bruker). Assignments are available within the
BMRB ID 1TSR.
Circular dichroism
All the CD experiments were followed with a Jasco J-815
spectropolarimeter (Easton, MD) fitted with an automatic 6-
position Peltier thermostated cell holder. The instrument was
calibrated with 10-camphorsulphonic acid. Far-UV CD data of
p53core-Y103G and p53core-WT were obtained using a 0.1 mm
path length cell (Quartz-Suprasil, Hellma UK Ltd) at
10.0uC60.1uC. Spectra were acquired using a continuous scan
rate of 50 nm/min and averaging at least ten scans. The response
time was 2 sec. The absorbance of the sample and buffer were
kept as low as possible: p53core-WT spectrum was carried out in
20 mM sodium phosphate (pH 6.8), 10 mM NaCl, 2 mM DTT
and recorded between 180 to 260 nm. Due to the presence of
precipitations of the p53core-L265A in low salt solution, the
spectrum was recorded between 190 to 260 nm in 20 mM sodium
phosphate (pH 6.8), 50 mM NaCl, 2 mM DTT. Each spectrum
was at least repeated with fresh samples. All spectra were corrected
by subtraction of the corresponding solvent spectrum obtained
under identical conditions. The signal is expressed in mean residue
ellipticity (deg.cm
2.dmol
21). Thermal denaturation experiments
were performed by following raw ellipticity at 210 nm (far UV)
using a 1 mm path length cell (Quartz-Suprasil, Hellma UK, Ltd.).
The temperature ranged from 10 to 80uC with steps of 0.4uC. The
CD signal was integrated for 8 sec. Buffer conditions were 20 mM
sodium phosphate (pH 6.8), 50 mM NaCl, 2 mM DTT. Thermal
denaturation is irreversible due to protein precipitation.
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